Symbiotec Pharmalab
Steroid + hormone API maker with strong cash conversion and clean balance sheet. Priced below Divi's — long-term compounder profile.
“Symbiotec Pharmalab: momentum beats fundamentals — a trader's IPO, not an investor's.”
- ▸Strong demand 13.8x
- ▸GMP +18.7% supports listing pop
- ▸Anchors took 35% — confident
- ▸17% growth — healthy
- ▸2 forensic red flags in DRHP footnotes
- ⚠ USFDA inspection pending at Indore unit
- ⚠ Top-3 molecules = 54% revenue
Educational only. Not investment advice. GMP is unofficial chatter, never a promise.
Demand — who is actually bidding?
Live from NSE's official bid feed. QIB is smart money — if QIB sleeps past Day 2, listing pop usually dies.
Issue structure — where does money go?
- ▸API expansion Indore (₹310 Cr)
- ▸R&D + USFDA remediation (₹90 Cr)
- Promoter 82% → 66% after IPO
Deep financials — does profit become cash?
| FY | REVENUE | PAT | MARGIN | ROE | ROCE | D/E | CFO |
|---|---|---|---|---|---|---|---|
| FY24 | ₹890 Cr | ₹112 Cr | 12.6% | 16.4% | 18.2% | 0.4x | ₹98 Cr |
| FY25 | ₹1042 Cr | ₹141 Cr | 13.5% | 18.1% | 20% | 0.3x | ₹122 Cr |
| FY26 | ₹1218 Cr | ₹178 Cr | 14.6% | 19.6% | 21.4% | 0.2x | ₹160 Cr |
Valuation vs listed peers
| COMPANY | P/E | P/B | ROE |
|---|---|---|---|
| Symbiotec Pharmalab (IPO) | — | — | 14.6% margin |
| Symbiotec | 31 | 5 | 19.6% |
| Divi's Labs | 48 | 8.1 | 18.4% |
| Laurus Labs | 36 | 5.4 | 14.2% |
Read it as: peers show what the market already pays for this business model. Full P/E math lands with the RHP parse (needs outstanding share count).
Risk dossier
- 01USFDA inspection pending at Indore unit
- 02Top-3 molecules = 54% revenue
Documents & filings
Primary sources — the same PDFs our dossier numbers come from.
Questions investors ask about Symbiotec Pharmalab
Should I apply for the Symbiotec Pharmalab IPO for listing gains?
Momentum supports it: QIB 22.1x, total 13.8x, GMP +18.7%. Consider one lot and booking half on a pop.
Is Symbiotec Pharmalab good for the long term?
Not yet — wait for cheaper re-entry or cleaner quarters.
What is the Symbiotec Pharmalab IPO price band and lot size?
₹938–₹988, lot of 15 shares (min ₹14,820). Open 24 Aug 2026 to 27 Aug 2026.
How do I check Symbiotec Pharmalab IPO allotment status?
On the MUFG Intime portal: select Symbiotec Pharmalab, enter PAN, application number, or DP/Client ID, solve the captcha. Results go live 6–10 PM on allotment evening (issue closed 27 Aug 2026). BSE's application-status page works as fallback.
When is the Symbiotec Pharmalab listing date?
It listed at ₹988 (0%).
Who should apply?
- • Listing trader → yes, momentum is real
- • Long-term holder → wait for cheaper re-entry
- • First-time investor → learn by watching, not betting
Listing-day playbook
- • Opens +40%↑ → book half, keep rest at cost stop
- • Opens flat ±5% → hold only if long-term score ≥7
- • Opens discount → never average down Day 1